Stockwatch: AstraZeneca's Groundhog Day
This article was originally published in Scrip
The Groundhog Day ritual which took place in Philadelphia last week predicted another six weeks of winter. Had Punxsutawney Phil surveyed the public markets for life sciences on his way out of his burrow, he would have seen even more signs of a potential prolonged freeze ahead for some companies.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.